All In Biotech

Drug Trial Radar · NCT02954354

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza

Last checked: Nov 20, 2026Latest source record: May 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,436 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,436

Actual

Start

Dec 8, 2016

Primary completion

Apr 4, 2017

Study completion Apr 24, 2017

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Nov 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus infection.

Conditions

  • Influenza

Interventions

  • Baloxavir MarboxilDrug

    2 to4 X 20-mg tablets taken orally

  • Placebo to Baloxavir MarboxilDrug

    2 to4 X 20-mg tablets taken orally

  • OseltamivirDrug

    75 mg capsules taken orally

  • Placebo to OseltamivirDrug

    Placebo capsules matching oseltamivir 75 mg capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Alleviation of Symptoms in Participants Randomized to Baloxavir or PlaceboTime frame: Initiation of study treatment up to Day 14
  2. Time to Alleviation of Symptoms in Adults Randomized to Baloxavir or OseltamivirTime frame: Initiation of study treatment up to Day 14

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.